5-Aminosalicylic Acid Azo-Coupled with a GPR109A Agonist Is a Colon-Targeted Anticolitic Codrug with a Reduced Risk of Skin Toxicity
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- MOLECULAR PHARMACEUTICS17(1) · pp.167 · 2020
- 피인용
- Web of Science 14Scopus 15
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 4.321
- ISSN
- 1543-8384
저자
- 정성근제1저자College of Pharmacy, Pusan National University, Busan, Republic of Korea
- 이한주College of Pharmacy, Pusan National University, Busan, Republic of Korea
- 김수진College of Pharmacy, Pusan National University, Busan, Republic of Korea
- 주상현College of Pharmacy, Pusan National University, Busan, Republic of Korea
- 김우성College of Pharmacy, Pusan National University, Busan, Republic of Korea
- Cho, HeeyeongBiotechnology & Therapeutic Division, Korea Research Institute of Chemical Technology, Daejeon 305-343, Republic of Korea
- Kim, Hyun YoungBiotechnology & Therapeutic Division, Korea Research Institute of Chemical Technology, Daejeon 305-343, Republic of Korea
- 허광범College of Pharmacy, Pusan National University, Busan, Republic of Korea
- 임은옥College of Pharmacy, Pusan National University, Busan, Republic of Korea
- 유진욱College of Pharmacy, Pusan National University, Busan, Republic of Korea
- 윤인수College of Pharmacy, Pusan National University, Busan, Republic of Korea
- 정연진교신저자College of Pharmacy, Pusan National University, Busan, Republic of Korea
초록
To develop a 5-aminosalicylic acid (5-ASA)-based anticolitic drug with enhanced therapeutic activity, a colon-targeted codrug constituting 5-ASA and a GPR109A agonist was designed. 5-ASA azo-coupled with nicotinic acid (ASA-azo-NA) was synthesized, and the colon specificity and anticolitic effects were evaluated. Approximately 89% of ASA-azo-NA was converted to 5-aminonicotinic acid (5-ANA) and 5-ASA after 24 h of incubation in the cecal contents. 5-ANA was identified as a GPR109A agonist (concentration that gives half-maximal response (EC50): 18 mu M) in a cell-based assay. Upon oral gavage of ASA-azo-NA (oral ASA-azo-NA) and sulfasalazine (oral SSZ), a colon-targeted 5-ASA prodrug, cecal accumulation of 5-ASA was comparable, and 5-ANA was barely detectable in the blood, while it was detected up to 62.7 mu M with oral 5-ANA. In parallel, oral ASA-azo-NA did not elicit an adverse skin response. In murine macrophage and human colon carcinoma cells, activation of GPR109A by 5-ANA elevated the level of the anti-inflammatory cytokine IL-10, suppressed NF-kappa B activation, and potentiated the inhibitory activity of 5-ASA on NF-kappa B. Oral ASA-azo-NA ameliorated rat colitis and was more effective than oral SSZ, which were substantially blunted following cotreatment with the GPR109A antagonist, mepenzolate. In conclusion, ASA-azo-NA is a colon-targeted anticolitic codrug with a reduced risk of skin toxicity induced by the GPR109A agonist, therapeutically surpassing a current 5-ASA-based anti-inflammatory bowel disease drug in a rat colitis model.
키워드
5-aminosalicylic acid5-aminonicotinic acidGPRI09Acolon-targeted drug deliverycodruginflammatory bowel diseaseNF-KAPPA-BNICOTINIC-ACIDDRUG-THERAPYBUTYRATERECEPTORNIACINPROCAINAMIDEPATHOGENESISINFLAMMATIONINHIBITIONGPR109A
식별자
- Scopus EID
- 2-s2.0-85076239254
- WoS UID
- 000506713600016



로그인
연구물 목록으로